AR047329A1 - Derivados de quinolinas para el tratamiento de enfermedades cardiovasculares. composiciones farmaceuticas - Google Patents
Derivados de quinolinas para el tratamiento de enfermedades cardiovasculares. composiciones farmaceuticasInfo
- Publication number
- AR047329A1 AR047329A1 ARP040104624A ARP040104624A AR047329A1 AR 047329 A1 AR047329 A1 AR 047329A1 AR P040104624 A ARP040104624 A AR P040104624A AR P040104624 A ARP040104624 A AR P040104624A AR 047329 A1 AR047329 A1 AR 047329A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- optionally substituted
- substituted
- independently selected
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 20
- 229910052736 halogen Inorganic materials 0.000 abstract 13
- 150000002367 halogens Chemical group 0.000 abstract 13
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 10
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 10
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 10
- 125000005010 perfluoroalkyl group Chemical group 0.000 abstract 10
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 9
- 125000001153 fluoro group Chemical group F* 0.000 abstract 8
- -1 -NR8R9 Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 7
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 abstract 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 5
- 229930192474 thiophene Chemical group 0.000 abstract 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 4
- 125000002252 acyl group Chemical group 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 4
- 125000004429 atom Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000001624 naphthyl group Chemical group 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 abstract 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- 101100439664 Arabidopsis thaliana CHR8 gene Proteins 0.000 abstract 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 2
- 150000001412 amines Chemical class 0.000 abstract 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 abstract 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 abstract 2
- IQZZFVDIZRWADY-UHFFFAOYSA-N isocoumarin Chemical compound C1=CC=C2C(=O)OC=CC2=C1 IQZZFVDIZRWADY-UHFFFAOYSA-N 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 abstract 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 abstract 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 abstract 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 abstract 1
- AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 abstract 1
- WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 abstract 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 abstract 1
- YBDQLHBVNXARAU-UHFFFAOYSA-N 2-methyloxane Chemical group CC1CCCCO1 YBDQLHBVNXARAU-UHFFFAOYSA-N 0.000 abstract 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical group CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 abstract 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- UZOFELREXGAFOI-UHFFFAOYSA-N 4-methylpiperidine Chemical group CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 1
- 229920001774 Perfluoroether Polymers 0.000 abstract 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 abstract 1
- 235000008206 alpha-amino acids Nutrition 0.000 abstract 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 abstract 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 abstract 1
- 150000003248 quinolines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 abstract 1
- YBDQLHBVNXARAU-ZCFIWIBFSA-N tetrahydro-2-methyl-2H-pyran Chemical group C[C@@H]1CCCCO1 YBDQLHBVNXARAU-ZCFIWIBFSA-N 0.000 abstract 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000005309 thioalkoxy group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Los compuestos pertenecen a la categoría de los derivados de quinolinas utilizados en el tratamiento de enfermedades mediadas por LXR, particularmente enfermedades cardiovasculares. Composiciones farmacéuticas. Reivindicacion 1: Un compuesto de la formula (1), el cual tiene la estructura, en donde: R1 es -H o C1-3 alquilo; X1 es un enlace C1-5 alquilo, -C(O)-, -C(=CR8R9)-, -O-, -S(O)t-, -NR8-, -CR8R9-, -CHR23, -CR8(OR9)-, -C(OR8)2-, -CR8(OC(O)R9)-, -C=NOR9-, -C(O)NR8-, -CH2O-, -CH2S-, -CH2NR8- , -OCH2-, -SCH2-, -NR8CH2-, o una formula (2); R2 es H, es alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, -CH2OH, arilalquilo C7-11, fenilo, naftilo, perfluoroalquilo C1-3, CN, C(O)NH2, CO2R12 o fenilo sustituido independientemente por uno o más de los grupos independientemente seleccionados de C1-3 alquilo, C2-4 alquenilo, C2-4 alquinilo, C1-3 alcoxi, C1-3 perfluoroalquilo, halogeno, -NO2, -NR8R9, -CN, -OH, y C1-3 alquilo sustituidos con 1 a 5 átomos de fluor, o R2 es un heterociclo seleccionado del grupo que consiste de piridina, tiofeno, bencisoxazol, benzotiofeno, oxadiazol, pirrol, pirazol, imidazol y furano, cada uno de los cuales pueden estar opcionalmente sustituido con uno a tres grupos independientemente seleccionados de C1-3 alquilo, C1-3 alcoxi, C1-3 perfluoroalquilo, halogeno, -NO2, -NR8R9, -CN, y C1-3 alquilo sustituidos con 1 a 5 átomos de fluor; X2 es un enlace o -CH2-; R3 es fenilo, naftilo, o fenilo o naftilo sustituido independientemente por uno a cuatro grupos independientemente seleccionados de C1-3 alquilo, hidroxi, fenilo, acilo, halogeno, -NH2, -CN, -NO2, C1-3 alcoxi, C1-3 perfluoroalquilo, C1-3 alquilo sustituidos con 1 a 5 átomos de fluor, NR14R15, -C(O)R10, -C(O)NR10R11, - C(O)NR11A, -C=CR8, -CH=CHR8, -WA, -C:::CA, -CH=CHA, -WYA, -WYNR11-A, -WYR10, -WY(CH2)jA, -WCHR11(CH2)jA, -W(CH2)jA, -W(CH2)jR10, -CHR11W(CH2)jR10, -CHR11W(CH2)jA, -CHR11NR12YA, -CHR11NR12YR10, pirrol, -W(CH2)jA(CH2)kD(CH2)pZ, - W(CR18R19)A(CH2)kD(CH2)pZ, -(CH2)jWA(CH2)kD(CH2)pZ, -CH=CHA(CH2)kD(CH2)pZ, -C:::CA(CH2)kD(CH2)pZ, -W(CH2)jC:::CA(CH2)kD(CH2)pZ, y -W(CH2)jZ, o R3 es un heterociclo seleccionado de piridina, pirimidina, tiofeno, furano, benzotiofeno, indol, benzofurano, bencimidazol, benzotiazol, benzoxazol, y quinolina, cada uno de los cuales pueden estar opcionalmente sustituido con uno a tres grupos independientemente seleccionados de C1-3 alquilo, C1-3 alcoxi, C1-3 hidroxi, fenilo, acilo, halogeno, -NH2, -CN, -NO2, C1-3 perfluoroalquilo, C1-3 alquilo sustituidos con 1 a 5 átomos de fluor, -C(O)R10, -C(O)NR10R11, -C(O)NR11A, -C=CR8, -CH=CHR8, -WA, -C:::CA, -CH=CHA, -WYA, -WYR10, -WY(CH2)jA, -W(CH2)jA, -W(CH2)jR10, -CHR11W(CH2)jR10, - CHR11W(CH2)jA, -CHR11NR12YA, -CHR11NR12YR10, -WCHR11(CH2)jA, -W(CH2)jA(CH2)kD(CH2)pZ, -W(CR18R19)A(CH2)kD(CH2)pZ, -(CH2)jWA(CH2)kD(CH2)pZ, -CH=CHA(CH2)kD(CH2)pZ, -C:::CA(CH2)kD(CH2)pZ, -W(CH2)jC:::CA(CH2)kD(CH2)pZ, y -W(CH2)jZ; W es un enlace, -O-, - S-, -S(O)-, -S(O)2-, -NR11-, o -N(COR12)-; Y es -CO-, -S(O)2-, -CONR13, -CONR13CO-, -CONR13SO2-, -C(NCN)-, -CSNR13, -C(NH)R13, o -C(O)O-; j es 0 a 3; k es 0 a 3; t es 0 a 2; D es un enlace, -CH=CH-, -C:::C-, -C=, -C(O)-, fenilo, -O-, -NH-, -S-, - CHR14-, -CR14R15-, -OCHR14-, -OCR14R15-, o -CH(OH)CH(OH)-; p es 0 a 3; Z es -CO2R11, -CONR10R11, -C(=NR10)NR11R12, -CONH2NH2, -CN, -CH2OH, -NR16R17, fenilo, CONHCH(R20)COR12, ftalimida, pirrolidin-2,5-diona, tiazolidin-2,4-diona, tetrazolil, pirrol, indol, oxazol, 2-tioxo-1,3-tiazolinin-4-ona, C1-7 aminas, C3-7 aminas cíclicas, o C1-3 alquilo sustituido con uno o dos grupos OH; en donde dicho pirrol está opcionalmente sustituido con uno o dos sustituyentes independientemente seleccionados del grupo que consiste de -CO2CH3, -CO2H, -COCH3, -CONH2 y -CN; en donde dichas C1-7 aminas están opcionalmente sustituidas con uno a dos sustituyentes independientemente seleccionados del grupo que consiste de -OH, halogeno, -OCH3, y -C:::CH; en donde dichos fenilo está opcionalmente sustituido con CO2R11, y en donde dicho C3-7 aminas cíclicas están opcionalmente sustituidas con uno o dos sustituyentes independientemente seleccionados del grupo que consiste de -OH, -CH2OH, C1-3 alquilo, -CH2OCH3, -CO2CH3, y -CONH2, y en donde dicho oxazol está opcionalmente sustituido con CH2CO2R11; A es fenilo, naftilo, tetrahidronaftilo, indano o bifenilo, cada uno de los cuales puede estar opcionalmente sustituido por uno a cuatro grupos independientemente seleccionados de halogeno, C1-3 alquilo, C2-4 alquenilo, C2-4 alquinilo, acilo, hidroxi, halogeno, -CN, -NO2, -CO2R11, -CH2CO2R11, fenilo, C1-3 perfluoroalcoxi, C1-3 perfluoroalquilo, -NR10R11, -CH2NR10R11, -SR11, C1-6 alquilo sustituidos con 1 a 5 átomos de fluor, C1-3 alquilo sustituido con 1 a 2 -OH grupos, C1-6 alcoxi opcionalmente sustituido con 1 a 5 átomos de fluor, o fenoxi opcionalmente sustituido con 1 a 2 CF3 grupos; o A es un heterociclo seleccionado de pirrol, piridina, pirridin-N-oxido, pirimidina, pirazol, tiofeno, furano, quinolina, oxazol, tiazol, imidazol, isoxazol, indol, benzo[1,3]-dioxol, benzo[1,2,5]-oxadiazol, isocromen-1-ona, benzotiofeno, benzofurano, 2,3-dihidrobenzo[1,4]-dioxina, bitienilo, quinazolin-2,4-91,3H]diona, y 3-H-isobenzofuran-1-ona, cada uno de los cuales puede estar opcionalmente sustituido por uno a tres grupos independientemente seleccionados de halogeno, C1-3 alquilo, acilo, hidroxi, -CN, -NO2, C1-3 perfluoroalquilo, -NR10R11, -CH2NR10R11, -SR11, C1-3 alquilo sustituidos con 1 a 5 átomos de fluor, C1-3 alcoxi opcionalmente sustituido con 1 a 5 átomos de fluor, R4, R5, y R6 son cada uno, independientemente, -H o -F; R7 es hidrogeno, C1-4 alquilo, C1-4 perfluoroalquilo, halogeno, -NO2, -CN, fenilo o fenilo sustituido con uno o dos grupos independientemente seleccionados de halogeno, C1-2 alquilo y OH; con la condicion de que si R7 es hidrogeno, entonces R3 es seleccionado de: a) fenilo sustituido por -W(CH2)jA(CH2)kD(CH2)pZ, -W(CR18R19)A(CH2)kD(CH2)pZ, -(CH2)jWA(CH2)kD(CH2)pZ, -CH=CHA(CH2)kD(CH2)pZ, -C:::CA(CH2)kD(CH2)pZ, o -W(CH2)jC:::CA(CH2)kD(CH2)pZ, en donde el residuo de fenilo está además opcionalmente sustituido con uno o más grupos independientemente seleccionados de C1-2 alquilo, C1-2 perfluoroalquilo, halogeno, y CN; y b) un heterociclo seleccionado de piridina, pirimidina, tiofeno, y furano, cada uno de los cuales está sustituido por uno de - W(CH2)jA(CH2)kD(CH2)pZ, -W(CR18R19)A(CH2)kD(CH2)pZ, -(CH2)jWA(CH2)kD(CH2)pZ, -CH=CHA(CH2)kD(CH2)pZ, -C:::CA(CH2)kD(CH2)pZ, o -W(CH2)jC:::CA(CH2)kD(CH2)pZ; además con la condicion que si X1R2 forma hidrogeno, entonces R3 es seleccionado de: a) fenilo sustituido por -W(CH2)jA(CH2)kD(CH2)pZ, -W(CR18R19)A(CH2)kD(CH2)pZ, -(CH2)jWA(CH2)kD(CH2)pZ, -CH=CHA(CH2)kD(CH2)pZ, -C:::CA(CH2)kD(CH2)pZ, o -W(CH2)jC:::CA(CH2)kD(CH2)pZ, en donde el residuo de fenilo está además opcionalmente sustituido con uno o más grupos independientemente seleccionados de C1-2 alquilo, C1-2 perfluoroalquilo, halogeno, y CN; y b) un heterociclo seleccionado de piridina, pirimidina, tiofeno, y furano, cada uno de los cuales está sustituido por uno de - W(CH2)jA(CH2)kD(CH2)pZ, -W(CR18R19)A(CH2)kD(CH2)pZ, -(CH2)jWA(CH2)kD(CH2)pZ, -CH=CHA(CH2)kD(CH2)pZ, -C:::CA(CH2)kD(CH2)pZ, o -W(CH2)jC:::CA(CH2)kD(CH2)pZ; además con la condicion que R3 y R7 no pueden ser ambos hidrogeno; cada R8 es independientemente -H, o C1-3 alquilo; cada R9 es independientemente -H, o C1-3 alquilo; cada R10 es independientemente -H, -OH, alcoxi C1-3, C1-7 alquilo, C3-7 alquenilo, C3-7 alquinilo, C3-7 cicloalquilo, -CH2CH2OCH3, 2-metil-tetrahidro-furano, 2- metil-tetrahidro-pirano, 4-metil-piperidina, morfolina, pirrolidina, o fenilo opcionalmente sustituido con uno o dos grupos alcoxi C1-3, en donde dicho C1-7 alquilo está opcionalmente sustituido con 1, 2 o 3 grupos independientemente seleccionados de C1-3 alcoxi, C1-3 tioalcoxi y CN; cada R11 es independientemente -H, C1-3 alquilo o R22; o R10 y R11, cuando están unidos al mismo átomo, junto a dicho átomo forman; un anillo saturado de 5 a 7 miembros, opcionalmente sustituido por 1 a 2 grupos independientemente seleccionados de C1-3 alquilo, OH y C1-3 alcoxi; o un anillo de 5 a 7 miembros que contiene 1 o 2 heteroátomos, opcionalmente sustituido por 1 a 2 grupos independientemente seleccionados de C1-3 alquilo, OH y C1-3 alcoxi; cada R12 es independientemente -H, o C1-3 alquilo; cada R13 es independientemente -H, o C1-3 alquilo; cada R14 y R15 es, independientemente, C1-7 alquilo, C3-8 cicloalquilo, C2-7 alquenilo, C2-7 alquinilo, -OH, -F, C7-14 arilalquilo, en donde dicho arilalquilo está opcionalmente sustituido con 1 a 3 grupos independientemente seleccionados de NO2, C1-6 alquilo, C1-3 perhaloalquilo, halogeno, CH2CO2R11, fenilo y C1-3 alcoxi, o R14 y R15 junto con el átomo al cual ellos están unidos pueden formar un alilo saturado de 3 a 7 miembros; cada R16 y R17 es, independientemente, hidrogeno, C1-3 alquilo, C1-3 alquenilo, C1-3 alquinilo, fenilo, bencilo o C3-8 cicloalquilo, en donde dicho C1-3 alquilo está opcionalmente sustituido con un grupo OH, y en donde dicho bencilo está opcionalmente sustituido con 1 a 3 grupos seleccionados de C1-3 alquilo y C1-3 alcoxi; o R16 y 17, junto con el átomo al cual ellos están unidos, pueden formar un heterociclo de 3 a 8 miembros el cual está opcionalmente sustituido con uno o dos sustituyentes independientemente seleccionados del grupo que consiste de C1-3 alquilo, -OH, CH2OH, -CH2OCH3, -CO2CH3, y -CONH2; cada R18 y R19 es, independientemente, C1-3 alquilo; cada R20 es independientemente H, fenilo, o la cadena lateral de un alfa aminoácido que existe de manera natural; cada R22 es independientemente arilalquilo opcionalmente sustituido con CH2COOH; y cada R23 es fenilo; o una sal farmacéuticamente aceptable de lo mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52900903P | 2003-12-12 | 2003-12-12 | |
US60029604P | 2004-08-10 | 2004-08-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR047329A1 true AR047329A1 (es) | 2006-01-18 |
Family
ID=34704262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040104624A AR047329A1 (es) | 2003-12-12 | 2004-12-10 | Derivados de quinolinas para el tratamiento de enfermedades cardiovasculares. composiciones farmaceuticas |
Country Status (18)
Country | Link |
---|---|
US (1) | US7576215B2 (es) |
EP (2) | EP2284157A1 (es) |
JP (1) | JP2007516258A (es) |
KR (1) | KR20070001922A (es) |
AR (1) | AR047329A1 (es) |
AU (1) | AU2004298486A1 (es) |
BR (1) | BRPI0417543A (es) |
CA (1) | CA2547518A1 (es) |
CR (1) | CR8410A (es) |
EC (1) | ECSP066635A (es) |
IL (1) | IL175892A0 (es) |
NO (1) | NO20062561L (es) |
PA (1) | PA8619901A1 (es) |
PE (1) | PE20050676A1 (es) |
RU (1) | RU2006124843A (es) |
SV (1) | SV2005001973A (es) |
TW (1) | TW200529845A (es) |
WO (1) | WO2005058834A2 (es) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1490047B1 (en) * | 2002-03-27 | 2009-12-30 | SmithKline Beecham Corporation | Certain pharmaceutically useful substituted aminoalkyl heterocycles |
WO2003082205A2 (en) * | 2002-03-27 | 2003-10-09 | Smithkline Beecham Corporation | Compounds and methods |
AU2003220558A1 (en) * | 2002-03-27 | 2004-06-03 | Smithkline Beecham Corporation | Amide compounds and methods of using the same |
WO2003082802A1 (en) * | 2002-03-27 | 2003-10-09 | Smithkline Beecham Corporation | Acid and ester compounds and methods of using the same |
JP4875978B2 (ja) * | 2004-03-15 | 2012-02-15 | 武田薬品工業株式会社 | アミノフェニルプロパン酸誘導体 |
JP4859665B2 (ja) | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
JP4793692B2 (ja) * | 2004-04-26 | 2011-10-12 | 小野薬品工業株式会社 | 新規なblt2介在性疾患、blt2結合剤および化合物 |
WO2005115145A2 (en) * | 2004-05-20 | 2005-12-08 | Wyeth | Quinone substituted quinazoline and quinoline kinase inhibitors |
ES2438739T3 (es) | 2005-06-28 | 2014-01-20 | Daiichi Sankyo Company, Limited | Procedimiento de prueba de ligando LXR |
GB0521083D0 (en) * | 2005-10-17 | 2005-11-23 | Novartis Ag | Organic compounds |
US20070093524A1 (en) * | 2005-10-25 | 2007-04-26 | Wyeth | 5-Lipoxygenase modulators |
US7939545B2 (en) | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
WO2008036238A2 (en) * | 2006-09-19 | 2008-03-27 | Wyeth | Use of lxr modulators for the prevention and treatment of skin aging |
BRPI0716833A2 (pt) * | 2006-09-19 | 2013-11-05 | Wyeth Corp | Uso de agonistas de lxr para o tratamento de osteoartrite |
TW200825054A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
WO2008070994A1 (en) * | 2006-12-14 | 2008-06-19 | Nps Pharmaceuticals, Inc. | Use of d-serine derivatives for the treatment of anxiety disorders |
US20090069373A1 (en) * | 2007-02-28 | 2009-03-12 | Wyeth | Quinoline Acids |
ES2320955B1 (es) * | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
US20080221127A1 (en) * | 2007-03-08 | 2008-09-11 | Plexxikon Inc | Ppar active compounds |
ES2329639B1 (es) * | 2007-04-26 | 2010-09-23 | Laboratorios Almirall S.A. | Nuevos derivados de 4,8-difenilpoliazanaftaleno. |
MX2009013959A (es) * | 2007-06-18 | 2010-03-09 | Richter Gedeon Nyrt | Derivados de sulfonil-quinolina. |
US8063220B2 (en) | 2007-06-22 | 2011-11-22 | Richter Gedeon Nyrt. | Sulfonyl-quinoline derivatives |
SI2220076T1 (sl) | 2007-11-15 | 2012-05-31 | Gilead Sciences Inc | Inhibitorji replikacije virusa humane imunske pomankljivosti |
UA100250C2 (uk) | 2007-11-16 | 2012-12-10 | Гілеад Сайнсіз, Інк. | Інгібітори реплікації вірусу імунодефіциту людини |
WO2009086138A1 (en) * | 2007-12-21 | 2009-07-09 | Wyeth | Benzimidazole compounds |
US20090209601A1 (en) * | 2008-02-15 | 2009-08-20 | Wyeth | Use of rxr agonists for the treatment of osteoarthritis |
EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
EP2113503A1 (en) * | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
JP5371118B2 (ja) | 2008-04-30 | 2013-12-18 | 興和株式会社 | キノリン化合物 |
CA2725111A1 (en) | 2008-05-29 | 2009-12-03 | Kowa Company, Ltd. | Substituted carbinol compound having a cyclic linker |
US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
HUE043569T2 (hu) * | 2008-06-16 | 2019-08-28 | Univ Tennessee Res Found | Vegyületek rák kezelésére |
US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
JP2012503595A (ja) * | 2008-07-28 | 2012-02-09 | シダンスク ユニバーシティ | 代謝病の治療用の化合物 |
JP5281647B2 (ja) * | 2008-09-08 | 2013-09-04 | 日本曹達株式会社 | 含窒素ヘテロ環化合物およびその塩並びに農園芸用殺菌剤 |
EP2352725A1 (en) * | 2008-11-07 | 2011-08-10 | Wyeth LLC | Quinoxaline-based lxr modulators |
RU2404971C2 (ru) * | 2008-12-02 | 2010-11-27 | ЗАО "Фарм-Синтез" | Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе |
WO2010065905A2 (en) * | 2008-12-05 | 2010-06-10 | Oregon Health & Science University | Compounds having antiparasitic or anti-infectious activity |
US8598354B2 (en) | 2008-12-05 | 2013-12-03 | University Of South Florida | Compounds having antiparasitic or anti-infectious activity |
US8551985B2 (en) | 2009-04-29 | 2013-10-08 | Kowa Company, Ltd. | Carbinol derivatives having heterocyclic linker |
MX2011011516A (es) | 2009-04-30 | 2011-11-18 | Astex Therapeutics Ltd | Compuestos farmaceuticos. |
JP2012531436A (ja) * | 2009-06-25 | 2012-12-10 | アムジエン・インコーポレーテツド | 複素環式化合物およびそれらのpi3k活性阻害剤としての使用 |
CN104592205A (zh) | 2010-03-01 | 2015-05-06 | Gtx公司 | 用于治疗癌的化合物 |
MX2012014801A (es) * | 2010-07-08 | 2013-01-29 | Wyeth Llc | Esteres de quinolina nuevos utiles para el tratamento de transtornos cutaneos. |
AU2011299703A1 (en) | 2010-09-07 | 2013-04-11 | Snu R&Db Foundation | Sesterterpene compounds and use thereof |
ES2379242B1 (es) * | 2010-09-28 | 2013-03-04 | Consejo Superior De Investigaciones Científicas (Csic) | Derivados de cromeno. |
HUE046292T2 (hu) | 2012-08-13 | 2020-02-28 | Univ Rockefeller | Melanóma kezelése és diagnosztizálása |
LT2909192T (lt) | 2012-10-16 | 2017-07-10 | Janssen Pharmaceutica Nv | Su metilenu sujungti rop-gama-t chinolinilo moduliatoriai |
ES2628365T3 (es) | 2012-10-16 | 2017-08-02 | Janssen Pharmaceutica N.V. | Moduladores de quinolinilo unidos a fenilo de ROR-GAMA-T |
CA2888480C (en) | 2012-10-16 | 2021-03-16 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of ror.gamma.t |
CN103965105A (zh) * | 2013-01-29 | 2014-08-06 | 中山大学 | 苯乙烯基喹啉衍生物及其在治疗阿尔茨海默病症中的应用 |
JPWO2014123203A1 (ja) * | 2013-02-06 | 2017-02-02 | 京都薬品工業株式会社 | 糖尿病治療薬 |
JP6835472B2 (ja) | 2013-03-05 | 2021-02-24 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 癌の処置のための組成物 |
KR20160070133A (ko) | 2013-10-15 | 2016-06-17 | 얀센 파마슈티카 엔.브이. | RORyt의 알킬 결합 퀴놀리닐 조절제 |
US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
CN105636952A (zh) | 2013-10-15 | 2016-06-01 | 詹森药业有限公司 | Rorγt的仲醇喹啉基调节剂 |
US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
EP3057422B1 (en) | 2013-10-15 | 2019-05-15 | Janssen Pharmaceutica NV | Quinolinyl modulators of ror(gamma)t |
US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
CA2939120A1 (en) | 2014-01-10 | 2015-07-16 | Rgenix, Inc. | Lxr agonists and uses thereof |
CN104036909B (zh) * | 2014-06-25 | 2016-09-28 | 桂林理工大学 | 磁性材料[Cu3(N3)6(DMF)2]n及合成方法 |
US10583102B2 (en) | 2014-10-06 | 2020-03-10 | The Johns Hopkins University | Targeting liver nuclear receptors as a treatment for wilson disease |
AU2017207291B2 (en) | 2016-01-11 | 2023-06-15 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
EP3246028A1 (en) * | 2016-05-18 | 2017-11-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinoline compounds for increasing insuline release |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
CA3056305A1 (en) * | 2017-05-12 | 2018-11-15 | Rti International | Diarylureas as cb1 allosteric modulators |
WO2019074241A1 (ko) * | 2017-10-11 | 2019-04-18 | 정원혁 | 페닐아세틸렌 유도체를 포함하는 pd-1과 pd-l1의 상호작용 억제제 |
WO2019089626A1 (en) * | 2017-10-30 | 2019-05-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Substituted quinoline analogs as aldehyde dehydrogenase 1a1 (aldh1a1) inhibitors |
WO2019104062A1 (en) | 2017-11-21 | 2019-05-31 | Rgenix, Inc. | Polymorphs and uses thereof |
EP3887401A2 (en) | 2018-11-26 | 2021-10-06 | Denali Therapeutics Inc. | Methods for treating dysregulated lipid metabolism |
TW202128161A (zh) | 2019-10-18 | 2021-08-01 | 美國加利福尼亞大學董事會 | 用於靶向病原性血管之化合物及方法 |
WO2021096589A1 (en) * | 2019-11-15 | 2021-05-20 | Georgia State University Research Foundation, Inc. | Small molecules polymerase inhibitors |
US11174220B2 (en) | 2019-12-13 | 2021-11-16 | Inspirna, Inc. | Metal salts and uses thereof |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6350351B2 (es) * | 1978-01-28 | 1988-10-07 | Sheru Intern Risaachi Maachatsupii Bv | |
US4407803A (en) * | 1981-08-17 | 1983-10-04 | Abbott Laboratories | Antiinflammatory 1-(quinolinyl)-2-pyrazoline derivatives |
DE3413078A1 (de) | 1984-04-06 | 1985-10-24 | Miles Laboratories, Inc., Elkhart, Ind. | Chromogene aminosaeure- und peptidester, verfahren zu deren herstellung, verwendung dieser verbindungen in analysenverfahren sowie mittel zum nachweis esterolytischer und/oder proteolytischer enzyme |
CA1336714C (en) * | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
US4761419A (en) * | 1987-12-07 | 1988-08-02 | Warner-Lambert Company | 6-(((substituted)quinolinyl)ethyl)-and ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
IL92544A0 (en) | 1988-12-08 | 1990-08-31 | Duphar Int Res | Piperazine derivatives,their preparation and pharmaceutical compositions containing them |
DE3905908A1 (de) * | 1989-02-25 | 1990-09-06 | Bayer Ag | Substituierte chinoline, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
US5753675A (en) * | 1989-03-03 | 1998-05-19 | Novartis Pharmaceuticals Corporation | Quinoline analogs of mevalonolactone and derivatives thereof |
DE3908298A1 (de) | 1989-03-14 | 1990-09-20 | Bayer Ag | Substituierte (chinolin-2-yl-methoxy)phenyl-n,n'-sulfonylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
DE3916663A1 (de) | 1989-05-23 | 1990-11-29 | Bayer Ag | Substituierte (chinolin-2-yl-methoxy)phenyl-acyl-sulfonamide und -cyanamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
DE3927369A1 (de) | 1989-08-19 | 1991-02-21 | Bayer Ag | Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe |
DE3927930A1 (de) | 1989-08-24 | 1991-02-28 | Bayer Ag | Cyclisch substituierte (chinolin-2-yl-methoxy)phenyl-essig-saeure-derivate |
DE3927931A1 (de) | 1989-08-24 | 1991-02-28 | Bayer Ag | Disubstituierte (chinolin-2-yl-methoxy)phenylessigsaeure-derivate |
WO1991004027A1 (en) | 1989-09-15 | 1991-04-04 | Pfizer Inc. | New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat) |
DE3935139A1 (de) | 1989-10-21 | 1991-04-25 | Bayer Ag | Substituierte (chinolin-2-yl-methoxy)phenyl-thioharnstoffe |
DE3935491A1 (de) | 1989-10-25 | 1991-05-02 | Bayer Ag | Substituierte (chinolin-2-yl-methoxy)phenyl-carbonylharnstoffe |
JPH03181465A (ja) * | 1989-12-11 | 1991-08-07 | Takeda Chem Ind Ltd | キノリン誘導体 |
GB9113137D0 (en) | 1990-07-13 | 1991-08-07 | Ici Plc | Thioxo heterocycles |
JPH04182469A (ja) | 1990-11-16 | 1992-06-30 | Terumo Corp | 新規なチオエステル化合物 |
JP2696150B2 (ja) | 1991-02-05 | 1998-01-14 | 株式会社大塚製薬工場 | キノリン誘導体 |
MX9200299A (es) * | 1991-02-07 | 1992-12-01 | Roussel Uclaf | Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. |
US6004979A (en) * | 1991-02-07 | 1999-12-21 | Hoechst Marion Roussel | Nitrogenous bicycles |
DE4105551A1 (de) | 1991-02-22 | 1992-08-27 | Bayer Ag | 2-substituierte chinoline, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
DE4139751A1 (de) | 1991-12-03 | 1993-06-09 | Bayer Ag, 5090 Leverkusen, De | Thiazolyl substituierte chinolylmethoxyphenylessigsaeurederivate |
DE4112533A1 (de) | 1991-04-17 | 1992-10-22 | Bayer Ag | Verfahren zur herstellung von enantiomerenreinen substituierten (chinolin-2-yl-methoxy)phenyl-essigsaeuren |
DE9290049U1 (de) * | 1991-04-26 | 1994-01-05 | Pfizer | 4-Aryl-3-(heteroarylureido)chinolin-Derivate |
US5366987A (en) * | 1991-08-22 | 1994-11-22 | Warner-Lambert Company | Isoxazolyl-substituted alkyl amide ACAT inhibitors |
DE4128681A1 (de) | 1991-08-29 | 1993-03-04 | Bayer Ag | Substituierte mandelsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
JP3130342B2 (ja) | 1991-10-04 | 2001-01-31 | 日産化学工業株式会社 | 動脈硬化性血管内膜肥厚抑制薬 |
JPH05128327A (ja) | 1991-11-01 | 1993-05-25 | Mitsubishi Electric Corp | Icカード |
JPH05130897A (ja) | 1991-11-11 | 1993-05-28 | Terumo Corp | チオール化合物測定用試薬組成物 |
DE4139749A1 (de) | 1991-12-03 | 1993-06-09 | Bayer Ag, 5090 Leverkusen, De | Chinolylmethoxyphenyl-essigsaeureamide |
DE4139750A1 (de) | 1991-12-03 | 1993-06-09 | Bayer Ag, 5090 Leverkusen, De | Chinolylmethoxyphenylessigsaeure-acylamide und -harnstoffe |
IL104369A0 (en) * | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
US5183825A (en) * | 1992-04-07 | 1993-02-02 | American Home Products Corporation | 4-arylmethyl-5-alkyl-3H-pyrazol-3-ones and hypoglycemic use |
EP0570112A1 (en) | 1992-04-23 | 1993-11-18 | Zeneca Limited | Cycloalkane derivatives |
DE4226519A1 (de) | 1992-08-11 | 1994-02-17 | Bayer Ag | 3-Substituierte Chinolylmethoxy-phenylessigsäurederivate |
JPH0692939A (ja) | 1992-09-16 | 1994-04-05 | Kyowa Hakko Kogyo Co Ltd | イミダゾール誘導体 |
DE4243279A1 (de) | 1992-12-21 | 1994-06-23 | Bayer Ag | Substituierte Triole |
ATE163412T1 (de) * | 1993-06-08 | 1998-03-15 | Sanofi Sa | Pyridazine als interleukin-1-beta verwandlungsenzym inhibitoren |
JPH0710870A (ja) | 1993-06-23 | 1995-01-13 | Asahi Glass Co Ltd | 新規アミノピリジン誘導体およびその塩 |
US5593992A (en) * | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
NZ274063A (en) * | 1993-09-17 | 1997-11-24 | Smithkline Beecham Corp | Cytokine suppressive anti-inflammatory drug binding protein (csbp) and its use |
JPH0789957A (ja) | 1993-09-22 | 1995-04-04 | Nissan Chem Ind Ltd | ビフェニルメチルアミン誘導体 |
US5453509A (en) | 1993-10-08 | 1995-09-26 | Synaptic Pharmaceutical Corporation | Functionalization of acyl pyridinium salts |
DE4411657A1 (de) | 1994-04-02 | 1995-10-05 | Basf Ag | Verfahren zur Herstellung von 6-Hydroxymethylchinolinen |
FR2722198B1 (fr) | 1994-07-08 | 1996-10-04 | Pf Medicament | 1derives de silylmethyl-anilines, le2fabrication, et leur utilisation co |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
DE19500122A1 (de) | 1995-01-04 | 1996-07-11 | Bayer Ag | Neue Pseudopeptide mit trifluormethyl-substituierten 2-Azabicyclooctan |
SK1296A3 (en) | 1995-01-04 | 1996-08-07 | Bayer Ag | Acyled pseudopeptides with trifluoromethyl-substituted 2-azabicyklooctane, manufacturing process thereof and medicaments containing these substances |
US5650415A (en) * | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
US5837719A (en) * | 1995-08-10 | 1998-11-17 | Merck & Co., Inc. | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
DE19532714A1 (de) | 1995-09-05 | 1997-03-06 | Bayer Ag | Kombination von 5-Lipoxygenase- und Leukotriensynthese Inhibitoren mit Glucocorticosteroiden |
JPH1067658A (ja) | 1995-09-13 | 1998-03-10 | Takeda Chem Ind Ltd | 免疫抑制剤 |
AR006520A1 (es) | 1996-03-20 | 1999-09-08 | Astra Pharma Prod | Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion. |
DE69738949D1 (de) | 1996-05-20 | 2008-10-09 | Darwin Discovery Ltd | Chinolincarboxamide als tnf-inhibitoren und als pde-iv inhibitoren |
EP0808627A2 (de) | 1996-05-22 | 1997-11-26 | Hoechst Aktiengesellschaft | Verwendung nicht-peptidischer Bradykinin-Antagonisten zur Behandlung und Prävention von chronisch-fibrogenetischen Lebererkrankungen, akuten Lebererkrankungen und den damit verbundenen Komplikationen |
JPH101471A (ja) | 1996-06-13 | 1998-01-06 | Green Cross Corp:The | N−[(キノリン−2−イル)フェニル]スルホンアミド類の結晶およびその製造方法 |
WO1998014430A1 (fr) | 1996-10-02 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Derives de pyrimidine |
DE69723863T2 (de) | 1996-11-06 | 2004-04-15 | Darwin Discovery Ltd., Slough | Chinoline und deren therapeutische verwendung |
EP0977989A1 (en) | 1997-02-04 | 2000-02-09 | Trega Biosciences, Inc. | 4-substituted-quinoline derivatives and 4-substitute-quinoline combinatorial libraries |
DE19709125A1 (de) | 1997-03-06 | 1998-09-10 | Bayer Ag | Substituierte Chinoline |
US6514977B1 (en) * | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
KR20010014030A (ko) * | 1997-06-19 | 2001-02-26 | 더글라스이.리디치 | 퀴놀린-인돌 항균제, 이들의 용도 및 조성물 |
AR016294A1 (es) | 1997-07-02 | 2001-07-04 | Smithkline Beecham Corp | Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion |
US6538022B1 (en) * | 1997-09-24 | 2003-03-25 | Orion Corporation | Compounds for deactivating phospholamban function on Ca-ATPase (phopholamban inhibitors) |
JP2002508366A (ja) | 1997-12-12 | 2002-03-19 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | キノリンピペラジンおよびキノリンピペリジン誘導体、それらの製造方法、ならびに複合的5−ht1a、5−ht1bおよび5−ht1d受容体アンタゴニストとしてのそれらの用途 |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
GB9819382D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds I |
GB9819384D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
EP1147094A1 (en) | 1999-01-15 | 2001-10-24 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
US6316503B1 (en) | 1999-03-15 | 2001-11-13 | Tularik Inc. | LXR modulators |
DE60008206T2 (de) | 1999-11-30 | 2004-12-02 | Pfizer Products Inc., Groton | Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase |
CA2392568A1 (en) * | 1999-12-13 | 2001-06-14 | Merck & Co., Inc. | Method for the prevention and/or treatment of atherosclerosis |
GB0002032D0 (en) | 2000-01-28 | 2000-03-22 | Zeneca Ltd | Chemical compounds |
WO2001056552A2 (en) | 2000-02-04 | 2001-08-09 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitors for treating breast cancer |
WO2001062234A2 (en) | 2000-02-24 | 2001-08-30 | Janssen Pharmaceutica N.V. | Dosing regimen |
JP2003525245A (ja) | 2000-02-29 | 2003-08-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤 |
CA2397349A1 (en) | 2000-02-29 | 2001-09-07 | Ivan David Horak | Farnesyl protein transferase inhibitor combinations with an her2 antibody |
EP1265611A2 (en) | 2000-02-29 | 2002-12-18 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with taxane compounds |
WO2001064197A2 (en) | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
CA2397448A1 (en) | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
JP2003525244A (ja) | 2000-02-29 | 2003-08-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗腫瘍性アルキル化剤とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤 |
EP1261356A2 (en) | 2000-02-29 | 2002-12-04 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with platinum compounds |
WO2001070227A1 (en) | 2000-03-17 | 2001-09-27 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
WO2001070228A1 (en) | 2000-03-17 | 2001-09-27 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
JP2001261654A (ja) | 2000-03-21 | 2001-09-26 | Mitsui Chemicals Inc | キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
US6495562B1 (en) * | 2000-04-25 | 2002-12-17 | Abbott Laboratories | Naphthamidine urokinase inhibitors |
AU2001262984A1 (en) * | 2000-05-03 | 2001-11-12 | Tularik, Inc. | Treatment of hypertriglyceridemia and other conditions using lxr modulators |
WO2002012191A1 (fr) | 2000-08-08 | 2002-02-14 | Shionogi & Co., Ltd. | Derives d'amines cycliques et utilisation |
GB0023918D0 (en) | 2000-09-29 | 2000-11-15 | King S College London | Antiparasitic compounds |
AU2002215328B2 (en) | 2000-10-12 | 2005-11-17 | Merck Sharp & Dohme Corp. | Aza- and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors |
WO2002030407A1 (en) | 2000-10-13 | 2002-04-18 | Astrazeneca Ab | ESTROGEN RECEPTOR-β LIGANDS |
EP1392713B1 (en) | 2001-05-03 | 2007-10-17 | The University of Chicago | Liver x receptor agonists |
JP2002371078A (ja) | 2001-06-12 | 2002-12-26 | Sankyo Co Ltd | キノリン誘導体及びキノロン誘導体 |
EP1270535A3 (de) | 2001-06-20 | 2004-02-18 | Clariant GmbH | Verfahren zur Herstellung von substituierten aromatischen Verbindungen |
FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
EP2168576A3 (en) * | 2001-09-14 | 2010-05-26 | Shionogi & Co., Ltd. | Tricyclic compounds for treating dyslipidemia and arteriosclerotic diseases |
AU2002336433A1 (en) * | 2001-10-08 | 2003-04-22 | Eli Lilly And Company | Tricyclic compounds useful for modulating lxr |
JP2005533007A (ja) * | 2002-03-27 | 2005-11-04 | スミスクライン・ビーチャム・コーポレイション | Lxr調節因子を用いる治療方法 |
-
2004
- 2004-12-10 AU AU2004298486A patent/AU2004298486A1/en not_active Abandoned
- 2004-12-10 CA CA002547518A patent/CA2547518A1/en not_active Abandoned
- 2004-12-10 KR KR1020067014042A patent/KR20070001922A/ko not_active Application Discontinuation
- 2004-12-10 AR ARP040104624A patent/AR047329A1/es not_active Application Discontinuation
- 2004-12-10 US US11/010,236 patent/US7576215B2/en not_active Expired - Fee Related
- 2004-12-10 SV SV2004001973A patent/SV2005001973A/es not_active Application Discontinuation
- 2004-12-10 JP JP2006544016A patent/JP2007516258A/ja active Pending
- 2004-12-10 RU RU2006124843/04A patent/RU2006124843A/ru not_active Application Discontinuation
- 2004-12-10 EP EP10181673A patent/EP2284157A1/en not_active Withdrawn
- 2004-12-10 EP EP04813688A patent/EP1692111A2/en not_active Withdrawn
- 2004-12-10 PA PA20048619901A patent/PA8619901A1/es unknown
- 2004-12-10 TW TW093138244A patent/TW200529845A/zh unknown
- 2004-12-10 BR BRPI0417543-3A patent/BRPI0417543A/pt not_active IP Right Cessation
- 2004-12-10 WO PCT/US2004/041399 patent/WO2005058834A2/en active Application Filing
- 2004-12-10 PE PE2004001236A patent/PE20050676A1/es not_active Application Discontinuation
-
2006
- 2006-05-19 CR CR8410A patent/CR8410A/es not_active Application Discontinuation
- 2006-05-24 IL IL175892A patent/IL175892A0/en unknown
- 2006-06-02 NO NO20062561A patent/NO20062561L/no not_active Application Discontinuation
- 2006-06-12 EC EC2006006635A patent/ECSP066635A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20050131014A1 (en) | 2005-06-16 |
US7576215B2 (en) | 2009-08-18 |
EP2284157A1 (en) | 2011-02-16 |
IL175892A0 (en) | 2006-10-05 |
CR8410A (es) | 2006-10-04 |
TW200529845A (en) | 2005-09-16 |
SV2005001973A (es) | 2005-11-04 |
AU2004298486A1 (en) | 2005-06-30 |
WO2005058834A3 (en) | 2005-11-17 |
PA8619901A1 (es) | 2005-11-25 |
BRPI0417543A (pt) | 2007-03-27 |
CA2547518A1 (en) | 2005-06-30 |
PE20050676A1 (es) | 2005-11-02 |
JP2007516258A (ja) | 2007-06-21 |
WO2005058834A2 (en) | 2005-06-30 |
NO20062561L (no) | 2006-09-08 |
RU2006124843A (ru) | 2008-01-20 |
ECSP066635A (es) | 2006-10-25 |
EP1692111A2 (en) | 2006-08-23 |
KR20070001922A (ko) | 2007-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR047329A1 (es) | Derivados de quinolinas para el tratamiento de enfermedades cardiovasculares. composiciones farmaceuticas | |
RU2383524C2 (ru) | Гексафторизопропанол-замещенные производные простых эфиров | |
PE20090884A1 (es) | Compuestos de indol como activadores de glucoquinasa | |
PE20061038A1 (es) | Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion | |
CY1116865T1 (el) | Παραγωγα υποκατεστημενης διβενζο-αζεπινης και βενζο-διαζεπινης χρησιμα ως αναστολεις της γαμμα-σεκρετασης | |
RU2312106C2 (ru) | Замещенные 4-алкоксиоксазолпроизводные в качестве агонистов ppar | |
PE20091952A1 (es) | Compuestos de tiazole y oxazole de sulfonamida de benzeno | |
PE20090297A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis | |
AR037882A1 (es) | Cis-imidazolinas | |
ES2655391T3 (es) | Inhibidores isoindolinona de fosfatidilinositol 3-quinasa | |
CO5170501A1 (es) | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO | |
PE20090042A1 (es) | Analogos de ciclopamina | |
ES2570127T3 (es) | Compuestos y composiciones como inhibidores de la proteína quinasa | |
AR040031A1 (es) | Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen | |
AR056327A1 (es) | Compuestos de nucleosidos para el tratamiento de infecciones virales | |
PE20090150A1 (es) | Compuestos derivados de oxadiazol | |
AR037418A1 (es) | Derivados de benzotiazol | |
PE20130375A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
EA200970493A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
PE20090630A1 (es) | Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion | |
AR056445A1 (es) | Derivados arilicos y heteroarilicos de 6 miembros para tratar virus | |
AR052330A1 (es) | Derivados de adamantano que comprenden quinoleinas sustituidas | |
PE20081475A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
AR083635A1 (es) | Compuestos y derivados sustituidos de isoxazolina que contienen azolin para combatir plagas animales | |
AR077463A1 (es) | Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |